Industry-Supported Symposium
Thomas Grader-Beck, MD
Johns Hopkins
Reisterstown, Maryland, United States
Disclosure information not submitted.
.png "Sara McCoy, MD;PhD;RhMSUS photo")
Sara McCoy, MD;PhD;RhMSUS
University of Wisconsin
Middleton, Wisconsin, United States
Disclosure information not submitted.
Please note: This session is not eligible for CME Credits through ACR.
This session will not be recorded for on-demand.
Historically, Sjögren’s disease (SjD) has been viewed as a condition with few symptoms beyond dry eyes and dry mouth. Recently, however, advancements have led to a heightened awareness of the systemic consequences and substantial quality of life impact of this condition. Insights into the underlying pathophysiology have led to the development of novel targeted therapies with the potential to improve outcomes for patients with SjD.
Join us in person for an engaging live symposium offered in conjunction with the American College of Rheumatology (ACR) Convergence 2025 where leading experts will explore the evolving evidence in the diagnosis and treatment of SjD.
This interactive 1.5-hour session will feature:
• A deep dive into SjD’s pathophysiology and emerging therapeutic targets in an innovative 2D animation
• A reflection on disease burden guided by video-based patient testimonials
• Interactive polling and live Q&A for direct engagement with faculty
• A downloadable Clinical Trials Pocket Guide to help you stay up to date on the latest evidence.
Don’t miss this opportunity to enhance your clinical expertise, engage with leading experts, and gain practical tools to improve the care of patients with SjD. In support of improving patient care, PRIME® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
PRIME® designates this Live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
PRIME & reg; has been authorized by the American Academy of PAs(AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 1.5 contact hours (which includes 0 hour of pharmacology).
This Application-based activity has been approved for 1.5 contact hours (0.1 CEUs) by PRIME® for pharmacists. The Universal Activity Number for this activity is pending . Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity by providing your NABP ID & DOB, which must be submitted within 60 days of completion. Pharmacists with questions can contact NABP customer service (help@nabp.pharmacy). Developed and offered by PRIME Education and supported by Novartis Pharmaceuticals Corporation. Not an official program of the ACR.
